Evaluation of Patient-Reported Outcomes in Patients with Relapsing Multiple Sclerosis Treated with Cladribine Tablets in the CLAWIR Study: 12-Month Interim Analysis

ConclusionThis real-world study demonstrates the effect of cladribine tablets over 12 months on PROs of fatigue, physical function, treatment satisfaction, and work productivity.Trial RegistrationThe CLAWIR study is registered at the German Federal Institute for Drugs and Medical Devices with the internal NIS number 7469.
Source: Advances in Therapy - Category: Drugs & Pharmacology Source Type: research